Indian Journal of Pharmacy and Pharmacology
  • Year: 2017
  • Volume: 4
  • Issue: 4

Assessment and analysis of adverse drug reactions in outpatient department of mental hospital of a tertiary care teaching institute of central India

13rd Year PG Student, Dept. of Pharmacology, M.G.M. Medical College, Indore

2Assistant Professor, Dept. of Psychiatry, M.Y. Hospital, M.G.M. Medical College, Indore, M.P

3Associate Professor & HOD, Dept. of Pharmacology, M.G.M. Medical College, Indore

*Corresponding Author: Email: dr.palirastogi73@gmail.com

Online published on 3 April, 2018.

Abstract

To monitor and analyze the adverse drug reactions (ADRs) in outpatient department of mental hospital of a tertiary care teaching institute of central India. To assess the causality between drug and adverse reaction using WHO-UMC scale.

A total of 209 adverse drug reactions were recorded in ICSR form obtained from CDSCO website in a period of 6 month from December 2016 to May 2017 in outpatient-department of mental hospital. Causality was assessed according to WHO-UMC causality scale.

Among 209 ADRs recorded 2 ADRs were excluded from further analysis because these were belonging to unlikely category of WHO-UMC causality scale. In this analysis 48.32% ADRs were certain, 32.05% ADRs were probable and 18.66% ADRs were possible. In this analysis 57% cases of ADRs were belonging to male while 43% cases were belonging to female. The maximum ADRs were reported in 21–30 years of age group (35.2%) followed by 31–40 years of age group (27%). The antipsychotics were responsible for maximum ADRs (71.02%), antidepressants were causing 12.07% of ADRs, antiepileptic were causing 14.5% of ADRs, ant manic drugs (lithium) were responsible for 2.4% cases of ADRs. CNS is most commonly affected system (44.92%), followed by metabolic side effects (37.68%). Olanzapine was the most common offending drug and weight gain was the commonest adverse drug reaction.

Keywords

Adverse drug reactions (ADRs), Psychotropic drugs, Analysis, CDSCO, Weight gain, Olanzapine